Company intelligence / Profile preview

Viridian Therapeutics

Waltham, Massachusetts, USAviridiantherapeutics.com ↗

Ownership: Public · VRDN
Employees: ~143
Development stage: Other

Overview

Viridian’s lead program, veligrotug (VRDN‑001), has completed two global Phase 3 trials for TED with positive topline results. A Biologics License Application (BLA) submission is planned for the second half of 2025. The subcutaneous follow-on candidate VRDN‑003 is in two global Phase 3 pivotal trials with topline data expected in the first half of 2026 and a BLA submission targeted by year-end 2026. Early-stage assets include novel FcRn inhibitors for autoimmune diseases.

Therapeutic areas: EndocrinologyImmunology
Modalities: Monoclonal antibodies (mAbs)Protein engineering/antibody discovery platforms
Industry: Biotech

Drug pipeline

22 assets

veligrotug

Approved

21 more assets in the full pipeline.

Financials

Market cap: $3.2B
Total revenue: $70.8M
Enterprise value: $2.5B

Beyond the preview

Go deeper on Viridian Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viridian Therapeutics.